Hisse Senetlerindeki Sıralama
#20654
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Hisse Fiyatı
$0.517
Son senkronizasyon: 2026-08-21
Ticaret Vaxart, Inc. (VXRT)
B piyasa değeri ile VXRT fiyatı
Piyasa Değeri Vaxart, Inc.(VXRT)
Piyasa Değeri: $125.14M
August 2026 itibarıyla Vaxart, Inc. şirketinin piyasa değeri $125.14M. Bu, verilerimize göre Vaxart, Inc. şirketini dünyanın en değerli 20654th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
Vaxart, Inc. piyasa değeri geçmişi (1981 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında VXRT
| VXRT’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.211T
|
+4,164,442.00%
|
|
|
|
|
$4.547T
|
+3,633,324.35%
|
|
|
|
|
$4.162T
|
+3,326,244.06%
|
|
|
|
|
$3.593T
|
+2,870,993.60%
|
|
|
|
|
$2.793T
|
+2,231,743.37%
|
